Did Jim Cramer Nail or Miss These 11 Stock Predictions?

Page 10 of 11

2. Eli Lilly and Company (NYSE:LLY)

Number of Hedge Fund Holders: 115

In that episode, a caller asked about Eli Lilly and Company (NYSE:LLY), particularly in relation to the competition with Novo Nordisk and its weight-loss drugs at the time. Cramer was enthusiastic back then, saying:

“We had this group 100X on the other day and they did a study about how people feel about Lilly versus Wegovy — about how they feel about Zepbound versus the product from Novo Nordisk — and without a doubt, in a head-to-head contest, Lilly is so far and away the winner. I just say you’ve got to own the stock. Let’s hope it comes in so we can buy more.”

Cramer’s bullish stance was premature as Eli Lilly fell 11.72%. Eli Lilly and Company (NYSE:LLY) remains a leader in obesity and diabetes treatment innovation, with Zepbound driving major growth in the pharmaceutical pipeline.

Despite the setbacks, Cramer recently advised a caller of the show to buy more. Here’s what he said on May 12:

“I want you to buy more… The reason why you want to buy it is because there was definitive data that came out last night about Novo Nordisk not being anywhere near as good as Eli Lilly when it comes to weight loss, which is what a lot of people are in the GLP for. And it was not reflected because the things were so crazed because of what the president announced. I think the stock could be up a hundred points when people realize, wait a second, it is definitively better than Novo. I would buy Eli Lilly handover fist.”

Page 10 of 11